SHIFT Newsroom · GLOBAL
GLP-1 Receptor Agonists May Have Different Effects on Cardiovascular, Renal, and Liver Outcomes in Type 2 Diabetes Patients
Research published on Europe PMC explores the association between GLP-1 receptor agonists and other antidiabetic medications on various health outcomes in patients with type 2 diabetes.
Researchers have published a study on the association between GLP-1 receptor agonists and other antidiabetic medications on cardiovascular, renal, and liver outcomes in patients with type 2 diabetes. The study, published on Europe PMC, aims to inform treatment decisions and improve patient outcomes.
What this means in the UK
This research may be relevant to UK patients with type 2 diabetes, as it could inform treatment decisions and help healthcare professionals understand the potential benefits and risks of different medications.
Known facts
- GLP-1 receptor agonists may have different effects on cardiovascular, renal, and liver outcomes compared to other antidiabetic medications.